Zoryl M 3 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3mg and Metformin 1000mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The prolonged-release (PR) formulation ensures a gradual and sustained release of active ingredients, promoting stable plasma drug levels and reducing dosing frequency, which may enhance patient compliance. Zoryl M 3 Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy with other antidiabetic agents. It is essential to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, particularly due to Glimepiride’s insulinotropic effect. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare lactic acidosis associated with Metformin. This medication should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.